keyword
MENU ▼
Read by QxMD icon Read
search

capecitabine

keyword
https://www.readbyqxmd.com/read/27906628/role-of-genomic-factors-beyond-thymidylate-synthase-in-the-prediction-of-response-to-5-fluorouracil
#1
Godefridus J Peters, K Smid, E Meijer, C J van Groeningen, L G Leon
5-Fluorouracil (5FU) is still a major drug in combinations regimens for the treatment of colorectal cancer (CRC) both in the adjuvant and palliative setting. 5FU or its oral prodrug capecitabine is usually combined with irinotecan/oxaliplatin and the novel agents bevacizumab/cetuximab. Although this improved the outcome, the overall prognosis in patients with metastasized disease is still relatively poor. Although the target for 5FU, thymidylate synthase was shown to have a predictive value, this could only predict response in a subset of patients...
December 2016: Nucleosides, Nucleotides & Nucleic Acids
https://www.readbyqxmd.com/read/27900205/efficacy-and-toxicity-of-adjuvant-chemotherapy-in-elderly-patients-with-colorectal-cancer-the-accore-study
#2
C M Lund, D Nielsen, C Dehlendorff, A B Christiansen, F Rønholt, J S Johansen, K K Vistisen
BACKGROUND: Elderly patients with primary colorectal cancer (CRC) are less frequently treated with adjuvant chemotherapy than younger patients due to concerns regarding toxicity and efficiency. We investigated how age, performance status (PS) and comorbidity influence treatment outcomes. PATIENTS AND METHODS: A retrospective single-centre study of 529 patients with stages II-III CRC treated with adjuvant chemotherapy (5-fluorouracil/capecitabine+/÷oxaliplatin) from 2001 to 2011 at Herlev Hospital, Denmark...
2016: ESMO Open
https://www.readbyqxmd.com/read/27898365/capillary-electrophoresis-with-online-stacking-in-combination-with-agnps-mcm-41-reinforced-hollow-fiber-solid-liquid-phase-microextraction-for-quantitative-analysis-of-capecitabine-and-its-main-metabolite-5-fluorouracil-in-plasma-samples-isolated-from-cancer
#3
Mehrdad Forough, Khalil Farhadi, Rahim Molaei, Hedayat Khalili, Ramin Shakeri, Asghar Zamani, Amir Abbas Matin
The purpose of this study is the development and validation of a simple, novel, selective and fast off-line microextraction technique combining capillary electrophoresis with in-column field-amplified sample injection (FASI) for the simultaneous determination of capecitabine (CAP) and its active metabolite, 5-Fluorouracil (5-FU), in human plasma. At the moment, there is a lack of using cost-effective CE tool combined with novel miniaturized sample clean-up techniques for analysis of these important anti-cancer agents in plasma samples...
November 18, 2016: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/27898006/immobilization-of-neutral-protease-from-bacillus-subtilis-for-regioselective-hydrolysis-of-acetylated-nucleosides-application-to-capecitabine-synthesis
#4
Teodora Bavaro, Giulia Cattaneo, Immacolata Serra, Ilaria Benucci, Massimo Pregnolato, Marco Terreni
This paper describes the immobilization of the neutral protease from Bacillus subtilis and its application in the regioselective hydrolysis of acetylated nucleosides, including building blocks useful for the preparation of anticancer products. Regarding the immobilization study, different results have been obtained depending on the immobilization procedure. Epoxy hydrophobic carriers gave a poorly stable derivative that released almost 50% of the immobilized protein under the required reaction conditions. On the contrary, covalent immobilization on a differently activated hydrophilic carrier (agarose) resulted in very stable enzyme derivatives...
November 25, 2016: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/27891147/effect-of-neoadjuvant-chemoradiotherapy-with-capecitabine-versus-fluorouracil-for-locally-advanced-rectal-cancer-a-meta-analysis
#5
REVIEW
Guo-Chen Liu, Jun-Ping Yan, Qing He, Xin An, Zhi-Zhong Pan, Pei-Rong Ding
A meta-analysis was carried out to compare the efficacy and safety of capecitabine plus radiation with 5-fluorouracil (5-FU) plus radiotherapy (RT) as neoadjuvant treatment in locally advanced rectal cancer (LARC). We searched the Cochrane database, Ovid, Medline, Embase, ISI databases, and Chinese Biomedical Literature Database between January 1998 and October 2014. Trials of capecitabine compared with 5-FU plus RT as neoadjuvant treatment for LARC were considered for inclusion. RevMan software was used to analyze these data...
2016: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/27888622/quantification-and-expert-evaluation-of-evidence-for-chemopredictive-biomarkers-to-personalize-cancer-treatment
#6
Shruti Rao, Robert A Beckman, Shahla Riazi, Cinthya S Yabar, Simina M Boca, John L Marshall, Michael J Pishvaian, Jonathan R Brody, Subha Madhavan
Predictive biomarkers have the potential to facilitate cancer precision medicine by guiding the optimal choice of therapies for patients. However, clinicians are faced with an enormous volume of often-contradictory evidence regarding the therapeutic context of chemopredictive biomarkers.We extensively surveyed public literature to systematically review the predictive effect of 7 biomarkers claimed to predict response to various chemotherapy drugs: ERCC1-platinums, RRM1-gemcitabine, TYMS-5-fluorouracil/Capecitabine, TUBB3-taxanes, MGMT-temozolomide, TOP1-irinotecan/topotecan, and TOP2A-anthracyclines...
November 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27885876/predictors-and-survival-for-pathologic-tumor-response-grade-in-borderline-resectable-and-locally-advanced-pancreatic-cancer-treated-with-induction-chemotherapy-and-neoadjuvant-stereotactic-body-radiotherapy
#7
Eric A Mellon, William H Jin, Jessica M Frakes, Barbara A Centeno, Tobin J Strom, Gregory M Springett, Mokenge P Malafa, Ravi Shridhar, Pamela J Hodul, Sarah E Hoffe
BACKGROUND: Neoadjuvant therapy response correlates with survival in multiple gastrointestinal malignancies. To potentially augment neoadjuvant response for pancreas adenocarcinoma, we intensified treatment with stereotactic body radiotherapy (SBRT) following multi-agent chemotherapy. Using this regimen, we analyzed whether the College of American Pathology (CAP) tumor regression grade (TRG) at pancreatectomy correlated with established response biomarkers and survival. MATERIALS AND METHODS: We identified borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer patients treated according to our institutional clinical pathway who underwent surgical resection with reported TRG (n = 81, median follow-up after surgery 24...
November 25, 2016: Acta Oncologica
https://www.readbyqxmd.com/read/27879513/high-grade-neuroendocrine-carcinoma-of-the-lung-with-carcinoid-morphology-a-study-of-12-cases
#8
Anne Marie Quinn, Anshuman Chaturvedi, Daisuke Nonaka
Twelve lung neuroendocrine tumors with morphologic features of carcinoid tumors but with mitotic count >10/2 mm are reported. There were 7 males and 5 females, with age ranging from 56 to 78 years. Four cases were from never-smokers. All tumors showed architectural and cytomorphologic features of carcinoid tumor, including organoid nesting, insular, trabecular, or acinar growth, and tumor cells with low nucleocytoplasmic ratio, abundant cytoplasm, ovoid to round nuclei, and salt and pepper chromatin. Angulated or confluent nesting, insular or lobular growth pattern was also seen...
November 22, 2016: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/27878803/tissue-doppler-echocardiography-detects-subclinical-left-ventricular-dysfunction-in-patients-undergoing-chemotherapy-for-colon-cancer-insights-from-oncoecho-multicenter-study
#9
Edyta Płońska-Gościniak, Monika Różewicz, Jarosław Kasprzak, Andrzej Wojtarowicz, Katarzyna Mizia-Stec, Tomasz Hryniewiecki, Piotr Pysz, Andrzej Kułach, Artur Bodys, Violetta Sulżyc, Wojciech Braksator, Andrzej Szyszka, Beata Zaborska, Adrianna Gościńska-Szmagała, Maciej Siński, Dariusz Kosior, Ilona Kowalik, Zbigniew Gąsior
I BACKGROUND: Colorectal cancer (CRC) is the second most common cancer in women and the third in men in Poland. The role of chemotherapy (CTX) depends on stage of CRC: adjuvant CTX is a standard treatment in stage III and should also be considered in stage II with risk factors. AIM: The aim of the paper was to assess the cardiovascular consequences of CTX in CRC enrolled to the ONCOECHO multicenter study (2012 - 2014). To identify potential cardiotoxicity we focused on myocardial function, heart rhythm and conduction disorders and adverse cardiovascular events...
November 23, 2016: Kardiologia Polska
https://www.readbyqxmd.com/read/27868413/-progress-on-clinical-application-of-bevacizumab-for-the-treatment-of-refractory-cervical-cancer
#10
Bin He, Yanlan Chai, Tao Wang, Zhenxing Zhou, Zi Liu
Bevacizumab is increasingly used in recurrent, persistent or metastatic cervical cancer. The early retrospective case reports found that bevacizumab combined with 5-FU (including capecitabine) or paclitaxel was well tolerated and displayed encouraging anti-tumor activity in recurrent or persistent cervical cancer. Phase Ⅱ clinical trials showed that bevacizumab was well tolerated and active in the second- and third-line treatment of patients with recurrent cervical cancer. Large scale phase Ⅱ and phase Ⅲ clinical trials demonstrated that bevacizumab-containing chemotherapy was effective in the first- and second-line treatment of patients with persistent cervical cancer, prolonged survival time and improved remission rate...
May 25, 2016: Zhejiang da Xue Xue Bao. Yi Xue Ban, Journal of Zhejiang University. Medical Sciences
https://www.readbyqxmd.com/read/27864592/evaluation-of-5-fluorouracil-degradation-rate-and-pharmacogenetic-profiling-to-predict-toxicity-following-adjuvant-capecitabine
#11
Michela Roberto, Adriana Romiti, Andrea Botticelli, Federica Mazzuca, Luana Lionetto, Giovanna Gentile, Ida Paris, Rosa Falcone, Maria Bassanelli, Francesca Romana Di Pietro, Concetta Elisa Onesti, Elisabetta Anselmi, Serena Macrini, Maurizio Simmaco, Paolo Marchetti
BACKGROUND: On account of the lack of predictive biomarkers of toxicity, we investigated whether polymorphisms of genes involved in fluoropyrimidine metabolism and 5-fluorouracil (5-FU) degradation rate were associated with outcomes of adjuvant capecitabine in patients with early stage gastrointestinal cancers. METHODS: Genotyping of DPYD GIVS14A, MTHFR C677T and A1298C SNPs were performed by pyro-sequencing technology. PCR analysis was used for genotyping TYMS-TSER...
November 18, 2016: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27859657/capecitabine-and-adermatoglyphia-trouble-in-border
#12
C Mazza, F Slimano, L Visseaux, M A Ordan, D Botsen, F Grange, O Bouche
Capecitabine, an oral prodrug of 5-fluorouracil, is approved in stage III colon cancer (1) and metastatic colorectal and breast cancer (2) (3). Palmo-plantar erythrodysesthesia, also known as Hand Foot syndrome (HFS), is its most limiting toxicity. Although it is not life threatening, it can compromise efficacy because of dose reduction. It has been reported in pivotal trials in 53% of patients receiving capecitabine, requiring dose reduction in 17% of patients (2). This article is protected by copyright. All rights reserved...
November 17, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27859010/bevacizumab-combined-with-capecitabine-and-oxaliplatin-in-patients-with-advanced-adenocarcinoma-of-the-small-bowel-or-ampulla-of-vater-a-single-center-open-label-phase-2-study
#13
Pat Gulhati, Kanwal Raghav, Rachna T Shroff, Gauri R Varadhachary, Scott Kopetz, Milind Javle, Wei Qiao, Huamin Wang, Jeffrey Morris, Robert A Wolff, Michael J Overman
BACKGROUND: Capecitabine with oxaliplatin (CAPOX) has previously demonstrated clinical activity in patients with small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (AAC). Herein, the authors conducted a phase 2 trial to evaluate the benefit of adding bevacizumab to CAPOX. METHODS: In this phase 2, single-arm, single-center, open-label study, patients aged ≥18 years with untreated, advanced SBA or AAC were recruited. Patients received capecitabine at a dose of 750 mg/m(2) orally twice daily on days 1 to 14, oxaliplatin at a dose of 130 mg/m(2) intravenously on day 1, and bevacizumab at a dose of 7...
November 14, 2016: Cancer
https://www.readbyqxmd.com/read/27858906/combination-of-125i-brachytherapy-and-chemotherapy-for-unresectable-recurrent-breast-cancer-a-retrospective-control-study
#14
Qixing Tan, Qinghong Qin, Weiping Yang, Bin Lian, Qinguo Mo, Changyuan Wei
Recurrent breast cancer remains an incurable malignancy and cannot be removed by surgery in the majority of cases. This study aimed to explore the feasibility and efficacy of the combination of I brachytherapy and chemotherapy for the treatment of unresectable recurrent breast cancer. Patients with unresectable recurrent breast cancer treated between January 2011 and December 2014 with a combination of I brachytherapy and capecitabine or gemcitabine were evaluated and outcomes were compared with those of women treated with capecitabine or gemcitabine in conventional dose as a monotherapy...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27857025/efficacy-of-chemotherapy-in-patients-with-unresectable-or-metastatic-pancreatic-acinar-cell-carcinoma-potentially-improved-efficacy-with-oxaliplatin-containing-regimen
#15
Changhoon Yoo, Bum Jun Kim, Kyu-Pyo Kim, Jae-Lyun Lee, Tae Won Kim, Baek-Yeol Ryoo, Heung-Moon Chang
Purpose: Pancreatic acinar cell carcinoma (ACC) is a rare cancer of the exocrine pancreas. Because of its rare incidence, the efficacy of chemotherapy in this patient population has been largely unknown. Therefore, we retrospectively analyzed the outcomes of patients with advanced pancreatic ACC who received chemotherapy. Materials and Methods: Between January 1997 and March 2015, 15 patients with unresectable or metastatic pancreatic ACC who received systemic chemotherapy were identified in Asan Medical Center, Korea...
November 9, 2016: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/27849649/a-multicenter-phase-ii-study-of-gemcitabine-capecitabine-and-bevacizumab-for-locally-advanced-or-metastatic-biliary-tract-cancer
#16
Renuka V Iyer, Venkata K Pokuri, Adrienne Groman, Wen W Ma, Usha Malhotra, Dan M Iancu, Catherine Grande, Tanios B Saab
OBJECTIVES: Vascular endothelial growth factor overexpression, seen in 42% to 76% of biliary tract cancers (BTCs), correlates with poor survival. We explored the safety/efficacy and potential biomarkers for bevacizumab in combination with gemcitabine-capecitabine in advanced BTCs. PATIENTS AND METHODS: Inoperable stage III/IV BTC patients in our prospective study were given 1000 mg/m of gemcitabine (on days 1, 8), 650 mg/m of capecitabine (on days 1 to 14), and 15 mg/kg of bevacizumab (on day 1) in 21-day cycles...
November 15, 2016: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27848234/tolerability-of-capecitabine-monotherapy-in-metastatic-colorectal-cancer-a-real-world-study
#17
Laura W Leicher, Jacques C de Graaf, Wilko Coers, Metin Tascilar, Jan Willem B de Groot
BACKGROUND: Capecitabine monotherapy is a treatment option for selected patients with metastatic colorectal cancer (mCRC) and is administered to up to 17% of patients. Data are limited with regard to adverse events and dosing practices associated with capecitabine monotherapy in real-world situations. OBJECTIVES: The aim of this study was to provide real-world data on adverse event rates and dose adjustments/discontinuations associated with capecitabine monotherapy in patients with mCRC...
November 15, 2016: Drugs in R&D
https://www.readbyqxmd.com/read/27843573/cost-minimization-analysis-of-adjuvant-chemotherapy-regimens-given-to-patients-with-colorectal-cancer-in-japan
#18
Kosuke Takata, Ken-Ichi Fujita, Yutaro Kubota, Hiroo Ishida, Wataru Ichikawa, Ken Shimada, Takashi Sekikawa, Iori Taki-Takemoto, Daisuke Kamei, Shinichi Iwai, Yasutsuna Sasaki
BACKGROUND: Consideration of medical costs as well as effectiveness and adverse events is rapidly been becoming an important factor in the selection of chemotherapy regimens. However, practical data on the costs of chemotherapy are scarce. We clinically estimated the medical costs of 6 adjuvant chemotherapy regimens for colorectal cancer on the basis of clinical and cost-related data and compared their cost-effectiveness by cost-minimization analyses. METHODS: All patients who received adjuvant chemotherapy for colorectal cancer between April 2012 and May 2015 at four hospitals affiliated with Showa University were studied retrospectively...
2016: Journal of Pharmaceutical Health Care and Sciences
https://www.readbyqxmd.com/read/27836862/phase-i-study-of-epigenetic-priming-with-azacitidine-prior-to-standard-neoadjuvant-chemotherapy-for-patients-with-resectable-gastric-and-esophageal-adenocarcinoma
#19
Bryan J Schneider, Manish A Shah, Kelsey Klute, Allyson Ocean, Elizabeta Popa, Nasser K Altorki, Michael D Lieberman, Andrew Schreiner, Rhonda K Yantiss, Paul J Christos, Romae Palmer, Agnes Viale, Daoqi You, Pouneh Kermani, Joseph M Scandura
PURPOSE: Epigenetic silencing of tumor suppressor genes (TSGs) is an acquired abnormality observed in cancer and is prototypically linked to DNA methylation. We postulated that pre-treatment (priming) with 5-azacitidine would increase the efficacy of chemotherapy by reactivating TSGs. This study was conducted to identify a tolerable dose of 5-azacitidine prior to EOX (epirubicin, oxaliplatin, capecitabine) neoadjuvant chemotherapy in patients with locally-advanced esophageal/gastric adenocarcinoma (EGC)...
November 10, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27830368/adjuvant-treatment-for-resected-rectal-cancer-impact-of-standard-and-intensified-postoperative-chemotherapy-on-disease-free-survival-in-patients-undergoing-preoperative-chemoradiation-a-propensity-score-matched-analysis-of-an-observational-database
#20
Benjamin Garlipp, Henry Ptok, Frank Benedix, Ronny Otto, Felix Popp, Karsten Ridwelski, Ingo Gastinger, Christoph Benckert, Hans Lippert, Christiane Bruns
AIMS: Adjuvant chemotherapy for resected rectal cancer is widely used. However, studies on adjuvant treatment following neoadjuvant chemoradiotherapy (CRT) and total mesorectal excision (TME) have yielded conflicting results. Recent studies have focused on adding oxaliplatin to both preoperative and postoperative therapy, making it difficult to assess the impact of adjuvant oxaliplatin alone. This study was aimed at determining the impact of (i) any adjuvant treatment and (ii) oxaliplatin-containing adjuvant treatment on disease-free survival in CRT-pretreated, R0-resected rectal cancer patients...
November 9, 2016: Langenbeck's Archives of Surgery
keyword
keyword
20530
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"